查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571579

肺部给药系统市场规模、份额、趋势分析报告：按产品、按应用、按最终用途、按地区、细分市场预测，2024-2030年

Pulmonary Drug Delivery Systems Market Size, Share & Trends Analysis Report By Product (Inhalers, Nebulizers, Accessories), By Application (Asthma, Cystic Fibrosis), By End-use, By Region And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

肺部给药系统市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球肺部给药系统市场规模将达到723.3亿美元，2024年至2030年复合年增长率为4.6%。

慢性呼吸道疾病的盛行率不断上升预计将推动肺部药物输送系统（PDDS）的采用。据世界卫生组织称，全球有 2.35 亿人患有气喘。由于缺乏治疗选择，大多数与气喘相关的死亡发生在低收入和中等收入国家。这显示未来几年对肺部给药系统的潜在需求。

药物传输领域的技术进步预计将对肺部药物传输装置市场产生正面影响。这些进步包括引入聚集囊泡技术、MDI 电子剂量计数器、粒子工程和超临界流体技术。对新产品的需求不断增加、生活方式的改变、易用性和设施的改进等因素预计将提供利润丰厚的机会。

此外，公共和私人机构数量的增加也是推动肺部给药装置市场成长的主要因素。例如，亚太气喘、气喘和临床免疫学协会 (APAAACI) 等组织致力于为过敏、气喘和临床免疫学的临床和基础研究提供资讯。此类措施预计将增加新兴市场对呼吸药物输送设备的市场需求，并推动整体市场成长。

肺部给药系统市场报告重点：

  • 2023 年，吸入器细分市场占据最大市场占有率，达到 62.8%。与循环到血液中的注射剂不同，吸入器将药物直接输送到肺部。
  • 雾化器领域预计在预测期内复合年增长率最快，达到 5.4%。
  • 2023 年，慢性阻塞性肺病(COPD) 细分市场占据最大市场占有率。慢性阻塞性肺病是一种慢性疾病，需要持续的治疗和照护。
  • 预计气喘细分市场在预测期内将以最快的复合年增长率成长。气喘患者希望治疗方法易于携带、易于使用并且可以每天使用。
  • 2023年，医院和诊所领域占据市场主导地位。医院和诊所的医生提供的治疗可以帮助患者快速康復。
  • 北美肺部给药系统市场占主导地位，2023 年收益占有率最大，为 32.0%。患有气喘和 CODP 等慢性疾病患者数量不断增加，推动了该地区市场的成长。
  • 亚太肺部给药系统市场预计将显着成长。气喘患者和过敏性鼻炎患者数量的持续增加预计将成为推动市场成长的因素。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章肺部给药系统市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肺部给药系统市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肺给药系统市场：产品评估与趋势分析

  • 细分仪表板
  • 肺部给药系统市场：2023年及2030年产品波动分析
  • 吸入器
  • 喷雾器
  • 配件

第五章肺部给药系统市场：应用估计和趋势分析

  • 细分仪表板
  • 肺部给药系统市场：2023年及2030年应用变化分析
  • 气喘
  • 囊肿纤维化
  • 慢性阻塞性肺病（COPD）
  • 过敏性鼻炎
  • 肺动脉高血压
  • 其他的

第六章肺部给药系统市场：最终用途估计与趋势分析

  • 细分仪表板
  • 肺部给药系统市场：2023 年和 2030 年最终用途变化分析
  • 医院/诊所
  • 日间手术中心 (ASC)
  • 居家护理
  • 其他的

第七章肺给药系统市场：区域估计与趋势分析

  • 肺部给药系统市场占有率（按地区），2023 年和 2030 年，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 最新趋势与影响分析：主要市场参与企业
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • 3M
    • AstraZeneca
    • GSK plc.
    • Novartis AG
    • Koninklijke Philips NV
    • Boehringer Ingelheim International GmbH.
    • Teva Pharmaceutical Industries Ltd.
    • OMRON Healthcare, Inc.
    • PARI GmbH
    • Cipla
简介目录
Product Code: GVR-1-68038-587-8

Pulmonary Drug Delivery Systems Market Growth & Trends:

The global pulmonary drug delivery systems market size is expected to reach USD 72.33 billion by 2030, registering a CAGR of 4.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems (PDDS). As per WHO, 235 million people suffer from asthma globally. Majority of the asthma-related deaths occur in middle- to low-income countries due to a lack of treatment options. This shows the potential demand for pulmonary drug delivery systems in the coming years.

Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market. These advancements include the incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.

Furthermore, a rise in the number of public and private organizations is another major factor propelling the growth of the pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting the overall market growth.

Pulmonary Drug Delivery Systems Market Report Highlights:

  • The inhalers segment accounted for the largest market share of 62.8% in 2023. Unlike injections which circulate in the bloodstream, inhalers administer medicine straight to the lungs.
  • The nebulizers segment is expected to register the fastest CAGR of 5.4% during the forecast period.
  • The Chronic Obstructive Pulmonary Disease (COPD) segment accounted for the largest market share in 2023. COPD is a chronic disease that requires continuous treatment and care.
  • The asthma segment is projected to grow at the fastest CAGR over the forecast period. Asthma patients look for treatment options that are easy to carry and use, in their everyday routines.
  • The hospitals & clinics segment dominated the market in 2023. The treatment offered by doctors in hospitals and clinics helps in speedy recovery of patients.
  • North America pulmonary drug delivery systems market dominated the market with the largest revenue share of 32.0% in 2023. The increasing cases of chronic diseases such as asthma and CODP is attributing to the market growth in the region.
  • Asia Pacific pulmonary drug delivery systems market anticipated to witness significant growth. The continuous increase in the number of asthmatic and allergic rhinitis patients are factors expected to propel the market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pulmonary Drug Delivery Systems Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pulmonary Drug Delivery Systems Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pulmonary Drug Delivery Systems Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pulmonary Drug Delivery Systems Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Inhalers
    • 4.3.1. Inhalers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Nebulizers
    • 4.4.1. Nebulizers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Accessories
    • 4.5.1. Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pulmonary Drug Delivery Systems Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pulmonary Drug Delivery Systems Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Asthma
    • 5.3.1. Asthma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cystic Fibrosis
    • 5.4.1. Cystic Fibrosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Chronic Obstructive Pulmonary Disease (COPD)
    • 5.5.1. Chronic Obstructive Pulmonary Disease (COPD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Allergic Rhinitis
    • 5.6.1. Allergic Rhinitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Pulmonary Arterial Hypertension
    • 5.7.1. Pulmonary Arterial Hypertension Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pulmonary Drug Delivery Systems Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pulmonary Drug Delivery Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals & Clinics
    • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Surgical Centers (ASCs)
    • 6.4.1. Ambulatory Surgical Centers (ASCs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Home Care
    • 6.5.1. Home Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Other End Use Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pulmonary Drug Delivery Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Pulmonary Drug Delivery Systems Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Pulmonary Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. 3M
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. AstraZeneca
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. GSK plc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Novartis AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Koninklijke Philips N.V.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Boehringer Ingelheim International GmbH.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Teva Pharmaceutical Industries Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. OMRON Healthcare, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. PARI GmbH
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Cipla
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives